Cygnal Therapeutics to Present Poster at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting
CAMBRIDGE, Mass., Nov. 9, 2020 /PRNewswire/ -- Cygnal Therapeutics, the first company to build a platform to develop drugs in the new field of exoneural biology, will present a poster this week at the Society for Immunotherapy of Cancer (SITC) 35th Anniversary Annual Meeting. The conference will be held online as a virtual event. Cygnal's poster will discuss research on the development and use of novel monoclonal antibodies to block tumor-promoting interactions with Neuropilin-1, leading to significant tumor growth inhibition in vivo.
Title: A novel mechanism of Neuropilin-1 inhibition results in improved tumor growth inhibition in vivo
Registered event attendees can access the poster via their SITC event login. Cygnal's poster presenters will be available for questions online on Wednesday, November 11 from 5:15 to 5:45 p.m. ET and on Friday, November 13 from 4:40 to 5:10 p.m. ET.
To learn more about Cygnal and exoneural biology, please visit Cygnal's website.
About Cygnal Therapeutics
SOURCE Cygnal Therapeutics